{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06337097",
            "orgStudyIdInfo": {
                "id": "2023-1021"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2024-02687",
                    "type": "OTHER",
                    "domain": "NCI-CTRP Clinical Registry"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy",
            "officialTitle": "STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "strict-surveillance-with-troponin-during-immune-checkpoint-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-22",
            "studyFirstSubmitQcDate": "2024-03-28",
            "studyFirstPostDateStruct": {
                "date": "2024-03-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.",
            "detailedDescription": "Primary Objectives:\n\n* Myocarditis CTCAE version 5.0 grade \u2265 3\n* Ventricular tachycardia (\u2265 30 seconds)\n* Advanced atrioventricular block\n* Incident heart failure event\n* Cardiovascular mortality\n* Non-fatal sudden cardiac arrest\n* Acute coronary syndrome\n* Pericarditis\n* Pericardial tamponade\n\nSecondary Objectives:\n\n* Time from symptom onset to diagnosis of major adverse cardiovascular events\n* Time from symptom onset to diagnosis of myocarditis\n* Initial hospitalization duration for the adverse cardiovascular event from primary endpoint\n* Peak biomarker levels including troponin T, troponin I, creatine kinase, and creatine kinase myocardial band\n* Percentage of patients with negative workup for myocarditis\n* Percentage of patients requiring major cardiac testing including echocardiograms, cardiac magnetic resonance imaging, and/or invasive heart catheterization\n* Duration of interruption and/or discontinuation of immune checkpoint inhibitor therapy\n* Cancer progression free survival\n* Time to next cancer therapy"
        },
        "conditionsModule": {
            "conditions": [
                "Immune Checkpoint Therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "SCREENING",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 880,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Troponin Surveillance",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in Group 1, will have blood tests performed prior to each immune checkpoint inhibitor infusion for 12 weeks.",
                    "interventionNames": [
                        "Diagnostic Test: Troponin surveillance"
                    ]
                },
                {
                    "label": "Standard of Care",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in Group 2, will have standard of care testing for any heart-related side effects of immune checkpoint inhibitors.",
                    "interventionNames": [
                        "Other: Standard of care"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Troponin surveillance",
                    "description": "Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.",
                    "armGroupLabels": [
                        "Troponin Surveillance"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Standard of care",
                    "description": "Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.",
                    "armGroupLabels": [
                        "Standard of Care"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and adverse events (AEs)",
                    "description": "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",
                    "timeFrame": "Through study completion; an average of 1 year."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female patient \u226518 years old\n* Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic\n* Willingness to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding\n* Troponin T not available at screening or prior to randomization\n* Inability to comply with planned study procedures\n* Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment\n* Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study\n* Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nicolas Palaskas, MD",
                    "role": "CONTACT",
                    "phone": "(713) 606-3957",
                    "email": "nlpalaskas@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nicolas Palaskas, MD",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicolas Palaskas, MD",
                            "role": "CONTACT",
                            "phone": "713-606-3957",
                            "email": "nlpalaskas@mdanderson.org"
                        },
                        {
                            "name": "Nicolas Palaskas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "MD Anderson Cancer Center",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}